1. Latest News
  2. Submit Press Release

BiondVax to Start Second Phase II Clinical Trial for Universal Flu Vaccine

BiondVax Announces Receipt of IRB Ethics (“Helsinki”) Committee Approvals for the Initiation of Second Phase II Clinical Trial for Universal Influenza Vaccine. The trial will start in October 2011 with 120 participants over the age of 65.

 
PRLog - Aug. 30, 2011 - RAANANA, Israel -- BiondVax Announces Receipt of IRB Ethics (“Helsinki”) Committee Approvals for the Initiation of Second Phase II Clinical Trial for Universal Influenza Vaccine

Ness Ziona, Israel –  29 August 2011 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX), an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a universal influenza vaccine, today announced that it has received the approvals of the Ethics (“Helsinki”) Committees of the Institutional Review Boards (IRB) of both the Hadassah Clinical Research Center at Hadassah University Hospital in Jerusalem (“Hadassah”) and the Tel Aviv Sourasky Medical Center (“Ichilov”), to perform a Phase II clinical trial to evaluate the safety, immunogenicity and priming potential of BiondVax’s universal influenza vaccine candidate, the Multimeric-001.

The principal investigators conducting the clinical trial will be Prof. Yoseph Caraco, Director of the Hadassah Clinical Research Center (CRC) and Dr. Jacob Atsmon, Director of the Ichilov CRC.

The trial is designed to include a total of 120 participants, both male and female, 65 years of age and older.  Screening of the potential participants will commence immediately, with the first administrations of the vaccine expected to take place in October 2011.  The Company expects to be able to report headline results from this trial by the end of the first quarter of 2012.

Dr. Tamar Ben-Yedidia, BiondVax’s Chief Scientific Officer, said, “We are very pleased to have received the necessary approvals for the initiation of our second Phase II clinical trial, which follows the successful completion of our first Phase II trial a few months ago.  We are looking forward to continuing our progress towards the successful development of the world’s first truly universal influenza vaccine.”

For further information, please contact:

Danny Aronovic

Public Relations Consultant

shapira marketing

Tel: +972 9 899 5813

Mobile: +972 50 799 1121

danny@shapiramarketing.com

About BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals (“the Company”), a publicly-traded company (TASE: BNDX) based in Ness Ziona, Israel, is developing a proprietary, innovative Universal Influenza (“flu”) Vaccine, the Multimeric-001 vaccine, designed to provide multi-season and multi-strain protection against all human influenza virus strains, including both seasonal influenza strains as well as pandemic influenza strains.

BiondVax’s innovative technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.

BiondVax has successfully concluded one Phase IIa clinical trial, as well as two Phase I/II trials, in which the Multimeric-001 Universal Flu Vaccine was shown to be safe and immunogenic.  The Company is now preparing for further Phase II clinical trials to be conducted in 2011 and 2012.

For further information on BiondVax, please visit www.biondvax.com

# # #

BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDK) based in Rehovot, Israel, is developing a proprietary, innovative Universal Influenza (“flu”) Vaccine with the potential to provide protection against most human influenza virus strains.

--- End ---

Click to Share

Contact Email:
***@shapiramarketing.com Email Verified
Source:Dan Aronovic
Phone:+972-9-899 5813
Zip:43214
Location:Raanana - Center - Israel
Industry:Biotech, Health, Medical
Tags:flu, influenza, virus, vaccine, biondvax, universal influenza vaccine, Health, Contagion
Shortcut:prlog.org/11640926
Verified Account Email Address

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



Like PRLog?
9K2K1K
Click to Share